NanoViricides Inc. (NNVC)

[changes_iv]

Excellent story on advanced science and how it will benefit mankind! The Nanoviricides, Inc. Train will soon be leaving to a station closer to that 23rd Century future...

Duke researchers had been working on this for 10 years and had just received permission from the FDA to treat 10 patients, but for only one a month. (A Duke press release last May explained that the treatment was designed to capitalize “on the discovery that cancer cells have an abundance of receptors that work like magnets in drawing the poliovirus, which then infects and kills the cells. The investigational therapy uses an engineered form of the virus that is lethal to cancer cells, while harmless to normal cells. The therapy is infused directly into a patient’s tumor. The virus-based therapy also triggers the body’s immune system to attack the infected tumor cells.")

This is similar to your other post where the virus is programmed to destroy itself...

Its name is DAVEI - which stands for “Dual Action Virolytic Entry Inhibitor”- and it can pull a fast one on HIV. DAVEI was invented and tested by scientists from Drexel’s College of Engineering; School of Biomedical Engineering, Science and Health Systems; and College of Medicine, and is the latest in a new generation of HIV treatments that function by specifically destroying the virus without harming healthy cells.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92205384

Dr. Seymour was recently at Duke University, Fuqua School of Business

In another Company news, our CEO, Eugene Seymour, MD, MPH, is invited to speak at the Duke University Fuqua School of Business today afternoon. His talk will focus on policies that can help accelerate the development of pharmaceuticals against diseases that pharma companies would otherwise not have much interest in, or “orphan drug” development.

Dr. Seymour will discuss the economic incentives associated with orphan drug development, focusing on the importance of the Priority Review Voucher (PRV), and their relevance to the decision-making process of both small and large pharmaceutical and biotech companies. He will illustrate his arguments using the example of DengueCide™, the Company’s nanoviricide drug against dengue, that has been designated an “orphan drug” by the US FDA.

In addition to the incentives related to orphan drug status, the Company may be eligible to receive a Priority Review Voucher (PRV) in the USA, upon approval of a drug against dengue viruses. A PRV can be applied by the Company to another drug candidate to obtain a “priority review” to speed up the regulatory process for that other drug. A PRV can also potentially be sold to another pharmaceutical company to obtain an immediate financial benefit. The value of a PRV has been variously estimated to be between $200M to $600M for such transactions. ~ fool.com

We have "good news" coming, here and abroad!